We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
IONS Beats Q2 Earnings & Sales Estimates, Reiterates '26 Outlook
Read MoreHide Full Article
Key Takeaways
Ionis beat Q2 revenue and earnings estimates and reaffirmed its full-year 2026 guidance.
IONS saw Dawnzera sales rise, while Tryngolza's launch expanded after broader sHTG approval.
Ionis reported commercial revenue growth, supported by royalties and partnered program progress.
Ionis Pharmaceuticals (IONS - Free Report) reported second-quarter 2026 adjusted loss per share of 43 cents, narrower than the Zacks Consensus Estimate of a loss of 89 cents. In the year-ago period, the company had posted adjusted earnings of 86 cents.
The adjusted earnings/loss exclude compensation expenses related to equity awards. Including this special item, loss was 69 cents per share against the earnings of 70 cents in the year-ago period.
Excluding the Ono payment, total revenues rose 56% year over year, driven by commercial growth and payments tied to progress across partnered programs.
IONS Stock Performance
Year to date, the company’s shares are down 33% compared with the industry’s nearly 3% decline.
Image Source: Zacks Investment Research
Ionis’ Diverse Revenue Stream
The company has two wholly-owned marketed drugs — Tryngolza for familial chylomicronemia syndrome (FCS) and severe hypertriglyceridemia (sHTG), as well as Dawnzera for hereditary angioedema.
Ionis also earns royalties from partnered medicines. These include the spinal muscular atrophy (SMA) therapy Spinraza and the ALS drug Qalsody, marketed by Biogen (BIIB - Free Report) , as well as Wainua, developed and commercialized with AstraZeneca (AZN - Free Report) for polyneuropathy caused by hereditary transthyretin-mediated amyloidosis.
The company’s revenues are divided into two segments — commercial revenues and research and development (R&D) revenues.
Commercial revenues, which include net product sales, royalties and other commercial revenues, rose 15% year over year to $119 million.
R&D revenues, which include collaborative agreement revenues and Wainua joint-development revenues, fell 57% to $149 million.
IONS’ Tryngolza Sales Reflect Price Reset
Tryngolza generated net product sales of $5 million in the second quarter compared with $19 million in the year-ago period. The decline reflected a strategic wholesale acquisition cost reduction that took effect on April 1, 2026, ahead of the broader sHTG launch.
Following the drug's approval last month for the broader sHTG indication, management said the launch is off to an encouraging start. Management also noted that underlying FCS demand remained strong, with the highest number of new patient starts since launch, and expects sales to accelerate in the second half of 2026.
Ionis’ Dawnzera Launch Gains Momentum
Dawnzera generated net product sales of $26 million in the reported quarter, up 63% sequentially from $16 million in the first quarter of 2026.
Demand was supported by patients switching from other long-term prophylactic therapies, those previously relying only on on-demand treatment and treatment-naive patients. Management also highlighted a growing base of repeat prescribers, indicating physicians’ positive experience with the drug.
IONS’ Partnered Portfolio Supports Revenues
Royalty revenues increased 9% year over year to $76 million.
Spinraza royalties fell 2% year over year to $53 million, while Wainua royalties rose 60% to $16 million. Other royalty revenues were $7 million.
R&D Revenues Face a Tough Comparison
Collaborative agreement revenues were $133 million, down nearly 61% year over year. The sharp decline was primarily attributed to an upfront payment of $280 million received in the year-ago period from Ono for out-licensing rights to sapablursen, an investigational therapy for a rare blood cancer called polycythemia vera (PV).
Wainua joint-development revenues increased to $16 million, up 33% year over year.
IONS’ Costs Rise on Commercial Investments
Adjusted research, development and patent expenses declined nearly 3% year over year to $192 million, while adjusted selling, general and administrative expenses increased more than 60% to $130 million.
The higher SG&A expenses reflected investments supporting the commercialization of Tryngolza and Dawnzera, as well as launch preparations for zilganersen in Alexander disease.
Ionis Reiterates 2026 Outlook
Ionis reaffirmed its full-year 2026 revenue guidance of $875-$900 million. The company continues to expect Tryngolza's net product sales of $100-$110 million and Dawnzera's net product sales of $110-$120 million.
The company also reiterated its adjusted operating loss guidance of $425-$475 million. Operating expenses are expected to increase in the low-teens percentage range from 2025, while R&D expenses are projected to remain broadly consistent with the prior year.
Ionis continues to project year-end cash and investments of more than $1.6 billion while remaining on track for cash-flow breakeven in 2028.
Updates on IONS’ Wholly-Owned Pipeline
Some important wholly-owned candidates in Ionis’ pipeline include zilganersen and obudanersen. A regulatory filing seeking the FDA’s approval of zilganersen for Alexander disease is currently under review, with a final decision expected by Sept. 22, 2026.
Obudanersen is being evaluated in the phase III REVEAL study for treating a rare and serious neurodevelopmental disorder called Angelman syndrome. Data from the study is expected next year.
Ionis’ partner, GSK plc (GSK - Free Report) , is developing bepirovirsen as a potential treatment for patients with chronic hepatitis B virus. While the drug was invented by Ionis, GSK holds global development and marketing rights. A regulatory filing seeking approval for the GSK-partnered therapy is currently under FDA review. A final decision is expected by Oct. 26, 2026.
Pelacarsen, in partnership with Novartis, is being developed in a phase III study called HORIZON for elevated Lp (a)-driven cardiovascular disease. Data from the study is expected later this year.
View the Zacks #1 Rank List
Image: Bigstock
IONS Beats Q2 Earnings & Sales Estimates, Reiterates '26 Outlook
Key Takeaways
Ionis Pharmaceuticals (IONS - Free Report) reported second-quarter 2026 adjusted loss per share of 43 cents, narrower than the Zacks Consensus Estimate of a loss of 89 cents. In the year-ago period, the company had posted adjusted earnings of 86 cents.
The adjusted earnings/loss exclude compensation expenses related to equity awards. Including this special item, loss was 69 cents per share against the earnings of 70 cents in the year-ago period.
Quarterly revenues were $268 million, which beat the Zacks Consensus Estimate of $190.7 million. Yet, the reported figure fell nearly 41% year over year as the comparison was affected by an upfront payment of $280 million received from Japan-based Ono Pharmaceutical in the year-ago period.
Excluding the Ono payment, total revenues rose 56% year over year, driven by commercial growth and payments tied to progress across partnered programs.
IONS Stock Performance
Year to date, the company’s shares are down 33% compared with the industry’s nearly 3% decline.
Image Source: Zacks Investment Research
Ionis’ Diverse Revenue Stream
The company has two wholly-owned marketed drugs — Tryngolza for familial chylomicronemia syndrome (FCS) and severe hypertriglyceridemia (sHTG), as well as Dawnzera for hereditary angioedema.
Ionis also earns royalties from partnered medicines. These include the spinal muscular atrophy (SMA) therapy Spinraza and the ALS drug Qalsody, marketed by Biogen (BIIB - Free Report) , as well as Wainua, developed and commercialized with AstraZeneca (AZN - Free Report) for polyneuropathy caused by hereditary transthyretin-mediated amyloidosis.
The company’s revenues are divided into two segments — commercial revenues and research and development (R&D) revenues.
Commercial revenues, which include net product sales, royalties and other commercial revenues, rose 15% year over year to $119 million.
R&D revenues, which include collaborative agreement revenues and Wainua joint-development revenues, fell 57% to $149 million.
IONS’ Tryngolza Sales Reflect Price Reset
Tryngolza generated net product sales of $5 million in the second quarter compared with $19 million in the year-ago period. The decline reflected a strategic wholesale acquisition cost reduction that took effect on April 1, 2026, ahead of the broader sHTG launch.
Following the drug's approval last month for the broader sHTG indication, management said the launch is off to an encouraging start. Management also noted that underlying FCS demand remained strong, with the highest number of new patient starts since launch, and expects sales to accelerate in the second half of 2026.
Ionis’ Dawnzera Launch Gains Momentum
Dawnzera generated net product sales of $26 million in the reported quarter, up 63% sequentially from $16 million in the first quarter of 2026.
Demand was supported by patients switching from other long-term prophylactic therapies, those previously relying only on on-demand treatment and treatment-naive patients. Management also highlighted a growing base of repeat prescribers, indicating physicians’ positive experience with the drug.
IONS’ Partnered Portfolio Supports Revenues
Royalty revenues increased 9% year over year to $76 million.
Spinraza royalties fell 2% year over year to $53 million, while Wainua royalties rose 60% to $16 million. Other royalty revenues were $7 million.
R&D Revenues Face a Tough Comparison
Collaborative agreement revenues were $133 million, down nearly 61% year over year. The sharp decline was primarily attributed to an upfront payment of $280 million received in the year-ago period from Ono for out-licensing rights to sapablursen, an investigational therapy for a rare blood cancer called polycythemia vera (PV).
Wainua joint-development revenues increased to $16 million, up 33% year over year.
IONS’ Costs Rise on Commercial Investments
Adjusted research, development and patent expenses declined nearly 3% year over year to $192 million, while adjusted selling, general and administrative expenses increased more than 60% to $130 million.
The higher SG&A expenses reflected investments supporting the commercialization of Tryngolza and Dawnzera, as well as launch preparations for zilganersen in Alexander disease.
Ionis Reiterates 2026 Outlook
Ionis reaffirmed its full-year 2026 revenue guidance of $875-$900 million. The company continues to expect Tryngolza's net product sales of $100-$110 million and Dawnzera's net product sales of $110-$120 million.
The company also reiterated its adjusted operating loss guidance of $425-$475 million. Operating expenses are expected to increase in the low-teens percentage range from 2025, while R&D expenses are projected to remain broadly consistent with the prior year.
Ionis continues to project year-end cash and investments of more than $1.6 billion while remaining on track for cash-flow breakeven in 2028.
Updates on IONS’ Wholly-Owned Pipeline
Some important wholly-owned candidates in Ionis’ pipeline include zilganersen and obudanersen. A regulatory filing seeking the FDA’s approval of zilganersen for Alexander disease is currently under review, with a final decision expected by Sept. 22, 2026.
Obudanersen is being evaluated in the phase III REVEAL study for treating a rare and serious neurodevelopmental disorder called Angelman syndrome. Data from the study is expected next year.
Updates on IONS’ Partnered Drugs
Earlier this month, AstraZeneca and Ionis announced that the phase III CARDIO-TTRANSform study, which evaluated Wainua for cardiomyopathy caused by hereditary TTR amyloidosis, did not meet its primary endpoint. Both companies plan to analyze the full data set to better understand the results and intend to present the findings at the European Society of Cardiology (ESC) Congress next month.
Ionis’ partner, GSK plc (GSK - Free Report) , is developing bepirovirsen as a potential treatment for patients with chronic hepatitis B virus. While the drug was invented by Ionis, GSK holds global development and marketing rights. A regulatory filing seeking approval for the GSK-partnered therapy is currently under FDA review. A final decision is expected by Oct. 26, 2026.
Pelacarsen, in partnership with Novartis, is being developed in a phase III study called HORIZON for elevated Lp (a)-driven cardiovascular disease. Data from the study is expected later this year.
Ionis Pharmaceuticals, Inc. Price
Ionis Pharmaceuticals, Inc. price | Ionis Pharmaceuticals, Inc. Quote
IONS’ Zacks Rank
Ionis currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.